Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.